Evidence map›Paper›PMID 41321622›Full record

ArticleiScience2025

CDK7 is a novel therapeutic target in fibrolamellar carcinoma.

Manabu Nukaya, Patrick R Carney, Crystal Cafferty, Katerina Zahed, Isabelle Yun, David P Al-Adra, Noor A Kazim, Alaa R Farghli, Marina Chan, Austin Stram and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Targeting CDKs in the RNAPII transcription cycle.Nature reviews. Drug discovery · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Manabu NukayaDepartment of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Patrick R CarneyDepartment of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Crystal CaffertyDepartment of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Katerina ZahedDepartment of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Isabelle YunDepartment of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
David P Al-AdraDepartment of Surgery, Division of Transplant Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Noor A KazimCornell University College of Veterinary Medicine, Department of Biomedical Sciences, Ithaca, NY 14853, USA.
Alaa R FarghliCornell University College of Veterinary Medicine, Department of Biomedical Sciences, Ithaca, NY 14853, USA.
Marina ChanDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Austin StramCenter for Human Genomics and Precision Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Jeremy D KratzCenter for Human Genomics and Precision Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Mark E BerresBioinformatics Resource Center, University of Wisconsin Biotechnology Center, Madison, WI 53792, USA.
Andrew YenCornell University College of Veterinary Medicine, Department of Biomedical Sciences, Ithaca, NY 14853, USA.
Taranjit S GujralDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Praveen SethupathyCornell University College of Veterinary Medicine, Department of Biomedical Sciences, Ithaca, NY 14853, USA.
Christopher A BradfieldMcArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Sean M Ronnekleiv-KellyDepartment of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.

Funding

BLRD VA IK2 BX006146
6 · The paper itself

Abstract

Fibrolamellar Carcinoma (FLC) is a rare and deadly cancer that arises in young, otherwise healthy patients. For patients that cannot be treated with surgery, only 30%-45% survive to 5 years with current treatment options. These poor survival odds highlight the need for new therapeutic targets. Using patient samples, we identified that abnormal function of cyclin-dependent kinase 7 (CDK7) is a key component of pathways that are essential for FLC cancer cell identity and survival. Consequently, drug inhibitors of CDK7 suppressed these abnormal pathways and also caused cancer cell death in a dose-dependent manner. This held true in several patient-derived models of FLC. We then found that inhibition of CDK7 can combine with other drug candidates to increase the therapeutic response in FLC cells. Taken together, this suggests CDK7 is a promising target for future treatment in human FLC.

Indexed as

Biological sciencesCancerCancer systems biologyNatural sciencesSystems biology

Identifiers

PMID41321622
PMCPMC12663737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.